Vol. 10 No. 11-12 (2016): CUAJ December Suppl 7

Supplement-Introduction

Supplement-Review

For some writing tips and resources, click here

For advertising information, click here

JOB POSTINGS

NEW! Brockville General Hospital
Urologic Surgeon

NEW! McMaster Institute of Urology
Advanced Laparoscopic/Robotic and Endourology Fellowship

NEW! Trillium Health Partners
Associate Urologist

University of Manitoba
Full-time academic surgeon (expertise in urologic oncology)

University of Manitoba
Academic Urologist

Obtain CPD Credit! CUAJ now provides readers with Section 3 credits of the Maintenance of Certification (self-assessment) program with the RCPSC. Read the latest accredited article, answer the multiple-choice questionnaire, and log the self-learning activity in your Royal College MAINPORT account.

Vol. 10 No. 11-12 (2016): CUAJ December Suppl 7

Supplement-Introduction

Sunitinib: 10 years of clinical experience in the treatment of advanced renal cell carcinoma

Supplement-Review

First-line treatment options in metastatic renal cell cancer

Practical first-line management of renal cell carcinoma in a community practice

Treatment options in advanced renal cell carcinoma after first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors

Sunitinib side effects as surrogate biomarkers of efficacy

Sunitinib toxicity management – a practical approach

Can individualized sunitinib dose and schedule changes optimize outcomes for kidney cancer patients?

The next 10 years: Challenges for the future and overcoming resistance to targeted therapies for renal cell carcinoma

grouped_ads

Language